Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

Objective: To evaluate the efficacy and safety of monotherapy with adalimumab in patients with RA for whom previous DMARD treatment has failed. Methods: In a 26 week, double blind, placebo controlled, phase III trial, 544 patients with RA were randomised to monotherapy with adalimumab 20 mg every other week, 20 mg weekly, 40 mg every other week, 40 mg weekly, or placebo. The primary efficacy end point was ≥20% improvement in the ACR core criteria (ACR20 response). Secondary efficacy end points included ACR50, ACR70, EULAR responses, and the Disability Index of the Health Assessment Questionnaire (HAQ DI). Results: After 26 weeks, patients treated with adalimumab 20 mg every other week, 20 mg weekly, 40 mg every other week, and 40 mg weekly had significantly better response rates than those treated with placebo: ACR20 (35.8%, 39.3%, 46.0%, 53.4%, respectively v 19.1%; p⩽0.01); ACR50 (18.9%, 20.5%, 22.1%, 35.0% v 8.2%; p⩽0.05); ACR70 (8.5%, 9.8%, 12.4%, 18.4% v 1.8%; p⩽0.05). Moderate EULAR response rates were significantly greater with adalimumab than with placebo (41.5%, 48.2%, 55.8%, 63.1% v 26.4%; p⩽0.05). Patients treated with adalimumab achieved better improvements in mean HAQ DI than those receiving placebo (−0.29, −0.39, −0.38, −0.49 v −0.07; p⩽0.01). No significant differences were found between adalimumab and placebo treated patients for serious adverse events, serious infections, or malignancies. Injection site reaction occurred in 10.6% and 0.9% of adalimumab and placebo treated patients, respectively (p⩽0.05). Conclusion: Among patients with RA for whom previous DMARD treatment had failed, adalimumab monotherapy achieved significant, rapid, and sustained improvements in disease activity and improved physical function and was safe and well tolerated.

[1]  P. Emery,et al.  Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study , 2003, Annals of the rheumatic diseases.

[2]  H. Paulus,et al.  Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. , 2003, Clinical therapeutics.

[3]  A. Widmer,et al.  Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. , 2003 .

[4]  T. Pincus,et al.  Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[5]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[6]  G. Newsome.  Guidelines for the management of rheumatoid arthritis: 2002 update. , 2002, Journal of the American Academy of Nurse Practitioners.

[7]  P. van Riel,et al.  Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis. , 2002, Rheumatology.

[8]  L. Joosten,et al.  Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation , 2002, Annals of the rheumatic diseases.

[9]  R. Yood,et al.  Guidelines for the management of rheumatoid arthritis: 2002 Update. , 2002, Arthritis and rheumatism.

[10]  D. Furst,et al.  Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001) , 2001, Annals of the rheumatic diseases.

[11]  L. Kiemeney,et al.  The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[12]  L. Joosten,et al.  Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFα in patients with rheumatoid arthritis , 2001, Annals of the rheumatic diseases.

[13]  Larry W. Moreland,et al.  Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis , 2001 .

[14]  M. Weinblatt,et al.  Rheumatoid arthritis. , 2001, Lancet.

[15]  D. Roeber,et al.  Incidence of injection-site lesions in beef top sirloin butts. , 2001, Journal of animal science.

[16]  J. Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.

[17]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[18]  D. Furst,et al.  Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. , 1999, Annals of internal medicine.

[19]  D. M. van der Heijde,et al.  The original "DAS" and the "DAS28" are not interchangeable: comment on the articles by Prevoo et al. , 1998, Arthritis and rheumatism.

[20]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[21]  P. Riel,et al.  Development and Validation of Response Criteria in Rheumatoid Arthritis: Steps Towards an International Consensus on Prognostic Markers , 1996 .

[22]  M. Prevoo,et al.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. , 1996, Arthritis and rheumatism.

[23]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[24]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[25]  J J Anderson,et al.  The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials , 1993 .

[26]  P Tugwell,et al.  Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. , 1993, The Journal of rheumatology.

[27]  M. A. van 't Hof,et al.  Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. , 1990, Annals of the rheumatic diseases.

[28]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[29]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[30]  J. Fries,et al.  The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. , 1982, The Journal of rheumatology.